AzTrials
AzTrials

COPDPhase 4NCT01794780

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

A Phase 4 study testing LABA based treatment: indacaterol, LAMA based treatment: tiotropium and LABA/ICS based treatment: salmeterol/fluticasone in people with COPD, run by Novartis Pharmaceuticals at 2 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. Read more about this study

Who is it for?
Any age
Conditions the study is for
COPD
What is being tested?
LABA based treatment: indacaterol, LAMA based treatment: tiotropium and LABA/ICS based treatment: salmeterol/fluticasone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,229 participants
Where
2 sitesChina
Study dates
5 Feb 2013to 25 May 2015
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Willing and able to provide informed consent
  • Physician-diagnosis of COPD
  • COPD patients requiring long-acting bronchodilator treatment
  • Patients with spirometry available at baseline

Who cannot join

  • Patients who have a diagnosis of asthma.
  • Patients who had been hospitalized for a COPD exacerbation in the 4 weeks prior to Visit 1.
  • Current clinical diagnosis of other chronic respiratory illnesses
  • Concurrent participation in a clinical trial or use of an investigational drug.
  • Active malignancy or history of malignancy of any organ system
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential with no contraception Other protocol-defined inclusion/exclusion criteria may apply.

Trial locations and contacts

2 sites in 1 country.

China2 sites
  • Novartis Investigative Site

    Beijing, 100730

  • Novartis Investigative Site

    Zhengzhou

Other trials in China

About this study

This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.

The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set.

A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.

Conditions
COPD
Being tested
LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone, LABA/ICS based treatment: budesonide/formoterol, theophylline based treatment
Keywords
COPD, Chronic obstructive pulmonary disease (COPD),, Chronic obstructive lung disease (COLD),, Chronic obstructive airway disease (COAD),, Cronchitis,, Emphysema
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Emphysema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LABA based treatment: indacaterolDrug

    LABA based treatment: indacaterol

  • LAMA based treatment: tiotropiumDrug

    LAMA based treatment: tiotropium

  • LABA/ICS based treatment: salmeterol/fluticasoneDrug

    LABA/ICS based treatment: salmeterol/fluticasone

  • LABA/ICS based treatment: budesonide/formoterolDrug

    LABA/ICS based treatment: budesonide/formoterol

  • theophylline based treatmentDrug

    theophylline based treatment

  • Other treatmentDrug

    non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"

Study groups in NCT01794780
Study groupRoleWhat they receive
IndacaterolExperimentalLABA: Indacaterol, once a day, 150μg each time
Receives: Drug: LABA based treatment: indacaterol
Tiotropium BromideExperimentalLAMA: Tiotropium Bromide, once a day, 18 μg
Receives: Drug: LAMA based treatment: tiotropium
Salmeterol/FluticasoneExperimentalLABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg
Receives: Drug: LABA/ICS based treatment: salmeterol/fluticasone
Budesonide/ formoterolExperimentalBudesonide/formoterol, twice daily, two suction each time, 160/4.5 μg
Receives: Drug: LABA/ICS based treatment: budesonide/formoterol
Indacaterol +TiotropiumExperimentalIndacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg
Receives: Drug: LABA based treatment: indacaterol; Drug: LAMA based treatment: tiotropium
LABA/ICS (Or budesonide/ formoterol)+ TiotropiumExperimentalSalmeterol / fluticasone Or budesonide / formoterol
Receives: Drug: LAMA based treatment: tiotropium; Drug: LABA/ICS based treatment: salmeterol/fluticasone; Drug: LABA/ICS based treatment: budesonide/formoterol
Oral theophyllineExperimentalNot described
Receives: Drug: theophylline based treatment
Other treatmentExperimentalnon-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"
Receives: Drug: Other treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.

    Measured: Baseline,3 months

Secondary outcomes (5)
  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.

    Measured: Baseline,12 months

  2. COPD Exacerbation

    Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.

    Measured: Baseline,12 months

  3. Change in Health Status Questionnaire MMRC

    The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.

    Measured: Baseline,3,6,9,12 months

  4. Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score

    The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.

    Measured: Baseline,3,6,9,12 months

  5. Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.

    Measured: Baseline,3,6,9,12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2013 (estimated)
  2. Study start5 Feb 2013
  3. Primary completion25 May 2015
  4. Study completion25 May 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,229 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01794780
Sponsor's protocol ID
CQAB149BCN01
Status last verified
Aug 2019
First submitted
15 Feb 2013
Last updated
26 Sep 2019
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Han J, Dai L, Zhong N, Young D. Breathlessness or health status in chronic obstructive pulmonary disease: the impact of different definitions. COPD. 2015 Apr;12(2):115-25. doi: 10.3109/15412555.2014.974741. Epub 2014 Dec 4.

    PubMed 25474373

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing LABA based treatment: indacaterol, LAMA based treatment: tiotropium and LABA/ICS based treatment: salmeterol/fluticasone in people with COPD, run by Novartis Pharmaceuticals at 2 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Sep 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) (time frame: Baseline,3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01794780, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in